BioSpace News Archive

It was a particularly busy week for clinical trial updates, mostly because of several virtual conferences, including the virtual American Heart Association Scientific Sessions 2020 and The Society for Immunotherapy of Cancer’s Annual Meetings. Here’s a look.

Nkarta has treated its first patient in the first-in-human Phase I clinical trial of NKX101, an investigational immunotherapy designed to treat relapsed/refractory acute myeloid leukemia (AML) or higher-risk myelodysplastic syndromes.

Sanofi was formally charged over Depakine, its epilepsy drug, for not taking action when they first discovered the fetal risks when taken by pregnant women.

Emerging biotech companies have been finding creative ways to explode onto the stock exchange during the COVID-19 pandemic.

A study recently conducted at Mayo Clinic showed that dysfunctional Tissue Resident Memory (TRM) CD8 T cells are actually working against the elderly, reducing immunity and enabling residual chronic lung issues after respiratory infections such as COVID-19.

Synairgen announced today that its data from the SG016 trial was published in the journal The Lancet Respiratory Medicine. The trial, which included 101 hospitalized COVID-19 patients, looked at SNG001 as a potential treatment.

“As true leaders in our field, both companies came to an agreement which benefits our customers and brings clarity to the industry. ''It shows our common goal to make high quality iPSC therapies available at affordable cost to our customers. Additionally, we are pleased to expand the license-use of our innovative Nucleofector™ technology granted to FUJIFILM Cellular Dynamics

A group of Researchers in St. Louis published the results of a clinical trial evaluating antidepressant fluvoxamine, for early treatment for COVID-19.

A recent study found that Vitamin D deficiency may be associated with an increased COVID-19 risk.

The BioNTech scientist said his vaccine can “bash the virus over the head”.